You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 141 No. 4, April 2006 TABLE OF CONTENTS
  Archives
  •  Online Features
  Paper
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on ISI (3)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Hepatobiliary Surgery
 •Liver/ Biliary Tract/ Pancreatic Diseases
 •Alert me on articles by topic

Distal Splenorenal Shunt

Preferred Treatment for Recurrent Variceal Hemorrhage in the Patient With Well-Compensated Cirrhosis

David R. Elwood, MD; James J. Pomposelli, MD, PhD; Elizabeth A. Pomfret, MD, PhD; W. David Lewis, MD; Roger L. Jenkins, MD

Arch Surg. 2006;141:385-388.

Hypothesis  Distal splenorenal shunt (DSRS) is a safe and effective treatment for patients with Child-Pugh class A and B cirrhosis with recurrent variceal hemorrhage after failed transjugular intrahepatic portosystemic shunt.

Design  Retrospective case review.

Setting  Hepatobiliary surgery and liver transplantation department in a tertiary referral medical center.

Patients  Between August 1, 1985, and May 1, 2005, 119 patients with Child-Pugh class A and B cirrhosis underwent DSRS for recurrent variceal hemorrhage. Of these, 17 (14.3%) had thrombosed or failing transjugular intrahepatic portosystemic shunt prior to DSRS.

Intervention  Distal splenorenal shunt for recurrent variceal hemorrhage after failure of conservative management.

Main Outcome Measures  Morbidity, mortality, and subsequent liver transplantation rate.

Results  The overall perioperative morbidity rate was 31.5%. Thirteen patients (11.7%) developed encephalopathy and 6 (5.4%) had recurrent variceal hemorrhage. Other complications included portal vein thrombosis, pancreatitis, pancreatic pseudocyst, pneumonia, and wound infection. The 30-day operative mortality rate was 6.4% (n = 7). The 1-year survival rate was 85.9%. The incidence of DSRS for failed transjugular intrahepatic portosystemic shunt during the first 12 years of the study (1985-1997) was 11.1% (9/81). This proportion increased to 26.7% (8/30) during the second half of the study (1997-2005). During the 20-year period, 15 patients (13.5%) underwent liver transplantation a mean of 5.1 years after DSRS without an increase in morbidity or mortality after transplantation.

Conclusions  Distal splenorenal shunt may be the preferred treatment for recurrent variceal hemorrhage in the patient with well-compensated cirrhosis. In addition, DSRS does not cause increased morbidity or mortality in subsequent liver transplantation.


Author Affiliations: Division of Hepatobiliary Surgery and Liver Transplantation, Lahey Clinic Medical Center, Burlington, Mass.







HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.